A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Authors
Keywords
-
Journal
Nature Chemical Biology
Volume 10, Issue 9, Pages 760-767
Publisher
Springer Nature
Online
2014-07-17
DOI
10.1038/nchembio.1582
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib: First Global Approval
- (2014) Fiona Cameron et al. DRUGS
- Proteome-Wide Reactivity Profiling Identifies Diverse Carbamate Chemotypes Tuned for Serine Hydrolase Inhibition
- (2013) Jae Won Chang et al. ACS Chemical Biology
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
- (2013) Girija Dasmahapatra et al. BRITISH JOURNAL OF HAEMATOLOGY
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Functional interrogation of kinases and other nucleotide-binding proteins
- (2013) Jonathan S. Rosenblum et al. FEBS LETTERS
- Determining target engagement in living systems
- (2013) Gabriel M Simon et al. Nature Chemical Biology
- Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells
- (2013) Jonathan J Hulce et al. NATURE METHODS
- Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
- (2013) P. A. Schwartz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei
- (2013) Mari Nishino et al. eLife
- Diverse Functional Roles of Reactive Cysteines
- (2012) Nicholas J. Pace et al. ACS Chemical Biology
- Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
- (2012) Caterina Carmi et al. BIOCHEMICAL PHARMACOLOGY
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB
- (2012) Stuart A. Rushworth et al. CELLULAR SIGNALLING
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
- (2012) Tjeerd Barf et al. JOURNAL OF MEDICINAL CHEMISTRY
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- DAGLβ inhibition perturbs a lipid network involved in macrophage inflammatory responses
- (2012) Ku-Lung Hsu et al. Nature Chemical Biology
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
- (2011) Emeline Leproult et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Selective Inhibitors of GlutathioneS-Transferase Omega 1 That Impair Cancer Drug Resistance
- (2011) Katsunori Tsuboi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Click-generated triazole ureas as ultrapotent in vivo–active serine hydrolase inhibitors
- (2011) Alexander Adibekian et al. Nature Chemical Biology
- Global profiling of dynamic protein palmitoylation
- (2011) Brent R Martin et al. NATURE METHODS
- Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors
- (2011) D. A. Bachovchin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted covalent drugs of the kinase family
- (2010) Juswinder Singh et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Strategies for discovering and derisking covalent, irreversible enzyme inhibitors
- (2010) Douglas S Johnson et al. Future Medicinal Chemistry
- Quantitative reactivity profiling predicts functional cysteines in proteomes
- (2010) Eranthie Weerapana et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
- (2009) Kay Ahn et al. CHEMISTRY & BIOLOGY
- A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding
- (2009) S. Nakayama et al. DRUG METABOLISM AND DISPOSITION
- Covalent Modifiers: An Orthogonal Approach to Drug Design
- (2009) Michele H. Potashman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activity-Based Proteome Profiling of Potential Cellular Targets of Orlistat − An FDA-Approved Drug with Anti-Tumor Activities
- (2009) Peng-Yu Yang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Target profiling of small molecules by chemical proteomics
- (2009) Uwe Rix et al. Nature Chemical Biology
- Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
- (2008) Benjamin F. Cravatt et al. Annual Review of Biochemistry
- Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
- (2008) Wooyoung Hur et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Disparate proteome reactivity profiles of carbon electrophiles
- (2008) Eranthie Weerapana et al. Nature Chemical Biology
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now